<div>Health-care companies ticked up as traders rotated back into higher risk sectors.

 Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a new pill called orforglipron that has helped clinical-trial participants lose weight. 

 Danish rival Novo Nordisk, meanwhile, filed for FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity. CagriSema combines the main ingredient in Wegovy with cagrilintide, an experimental drug that mimics the amylin hormone, the body's appetite regulator. 

 Cannabis producers such as Tilray and Canopy Growth fell after President Donald Trump signed an executive order to reschedule marijuana as a lower-class drug, stopping short of permitting recreational sales. 
 Write to Rob Curran at rob.curran@dowjones.com 

 (END) Dow Jones Newswires12-18-25 1741ET</div>

诺和诺德公司

礼来

医疗股小幅上涨，因为交易者转向风险较高的行业。礼来和诺和诺德公司申请了 FDA 对新型肥胖治疗药物的批准。由于特朗普重新安排了大麻的分类，影响了休闲销售， cannabis 股票下跌

医疗保健板块上涨，但涨幅有限，因交易员寻求风险——医疗保健综述